Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Next Generation Single Molecule Imaging to Transform In Vitro Diagnosis

By LabMedica International staff writers
Posted on 15 Jun 2023

A groundbreaking multi-omic platform designed for in vitro diagnosis can rapidly detect disease biomarkers, leading to earlier diagnoses for a variety of life-threatening illnesses. More...

The state-of-the-art platform is based on SMi Systems’ (Cambridge, UK) advanced super-resolution optical technology that boasts unrivaled spatial (1.6 nanometres) and temporal (0.5 milliseconds) resolution. SMi’s automated, high-precision optical technology provides the capability to view single molecule interactions in real-time. SMi is leveraging this huge leap in optical technology to develop a diagnostic device that can identify single molecules associated with both infectious and non-infectious diseases. When paired with AI, the platform offers unparalleled quantification of disease-associated single molecules. Furthermore, its capacity to simultaneously differentiate between various diseases from a single sample and process hundreds of samples in mere minutes makes it a highly efficient diagnostic tool. SMi has developed proof-of-principle instruments and also demonstrated their effectiveness in detecting infectious diseases.

Single molecule resolution enables diseases to be detected much earlier. The resolution levels offered by SMi's technology are unprecedented and can be tailored to any molecular target, allowing individual particles to be visualized and counted directly for the first time. This offers clinicians undeniable proof of the existence of molecules associated with either infectious or non-infectious diseases. The fully automated system requires less than a second per sample to provide a diagnosis, marking a considerable improvement over less precise lateral flow tests and PCR tests that can take several minutes or even hours. With the ability to process up to 384 samples in just a few minutes, this technology could become a game-changer, particularly for large-scale patient sample screenings in healthcare settings.

“We’ve proved the success of our new platform in both respiratory diseases and cancer biomarker diagnosis, but we’re only just scratching the surface of what is possible using our single molecule imaging technology,” said Dr Andrew Thompson, Chief Executive Officer (CEO) at SMi.

Related Links:
SMi Systems 


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.